S&P 500
7,592.20
-0.13%
Dow Jones
50,883.20
-0.37%
Nasdaq 100
30,497.60
+0.02%
Russell 2000
2,908.51
+0.23%
FTSE 100
10,364.60
+0.28%
Nikkei 225
66,856.70
-0.55%

Investing

Deadline Extended in Valeant Offer for ISTA (VRX, ISTA)

Photo of Paul Ausick
By Paul Ausick Published

Two weeks ago Valeant Pharmaceuticals International, Inc. (NYSE: VRX) made an unsolicited all-cash offer of $6.50/share for ISTA Pharmaceuticals, Inc. (NASDAQ: ISTA), a maker of eye-care drugs. The offer valued ISTA at around $327 million, including ISTA’s debt, a premium of 68% over ISTA’s most recent closing price.

ISTA has refused Valeant’s offer, calling it “grossly inadequate” but the two companies have been meeting to discuss a deal. Valeant’s original deadline to shareholders has been extended from January 12th to January 31st.

With ISTA shares trading above $7, Valeant is going to have to sweeten the deal if it expects to have a chance of acquiring ISTA.

Follow 24/7 Wall St. on Google
Photo of Paul Ausick
About the Author Paul Ausick →

Paul Ausick has been writing for 247Wallst.com for more than a decade. He has written extensively on investing in the energy, defense, and technology sectors. In a previous life, he wrote technical documentation and managed a marketing communications group in Silicon Valley.

He has a bachelor's degree in English from the University of Chicago and now lives in Montana, where he fishes for trout in the summer and stays inside during the winter.

Continue Reading

Paul Ausick |

Valeant Launches Hostile Bid for ISTA (VRX, ISTA)

Valeant Pharmaceuticals International, Inc. (NYSE: VRX) has made an unsolicited all-cash offer of $6.50/share for ISTA Pharmaceuticals, Inc. (NASDAQ: ISTA),…

Paul Ausick |

Bausch + Lomb Nabs ISTA (ISTA, VRX)

Privately held Bausch + Lomb Inc. has made ISTA Pharmaceuticals Inc. (NASDAQ: ISTA) an offer it can’t refuse. The eye…

Paul Ausick |

Ista Pharma Gets Sweetened Offer from Valeant (ISTA, VRX)

A month ago drug maker Ista Pharmaceuticals Inc. (NASDAQ: ISTA) rejected a takeover bid of $6.50/share in cash from Canadian…

Chris Lange |

As Valeant Ups Salix Buyout, Will Endo Come Back?

Salix Pharmaceuticals and Valeant Pharmaceuticals have announced that they had entered into an agreement on their plan to merge based…

Chris Lange |

Salix Now Has 2 Merger Dance Partners

A new bid from Endo International has made the merger situation around Salix Pharmaceuticals much more complicated.

Paul Ausick |

Valeant Offers Even More for Botox-Maker Allergan

ThinkstockCanada-based Valeant Pharmaceuticals Inc. (NYSE: VRX) has raised its offer for Allergan Inc. (NYSE: AGN) for the second time this…

Paul Ausick |

Is Valeant About to Buy Maker of Female Viagra?

The Wall Street Journal reported Thursday morning that Canada-based Valeant Pharmaceuticals is preparing to pay $1 billion for the closely…

Jon C. Ogg |

Friday’s Top Ten Stocks on the Move (ADBE, ATHN, CVC, CAM, CRYP, ISTA, MRVL, RIMM, RRR, SINA)

Friday is turning out to be a big day with many stocks on the move for an options expiration date. …

Paul Ausick |

Valeant Offer Weaker After Allergan Earnings

In a sharply worded press release Monday morning, Valeant Pharmaceuticals said that it "can no longer tolerate" statements from Allergan…

Top Gaining Stocks

MGM Resorts
MGM • Vol: 27,683,097
CDW
CDW • Vol: 3,240,293
Datadog
DDOG • Vol: 11,190,990
Gartner
IT • Vol: 2,031,591
Dell Technologies
DELL • Vol: 20,848,965

Top Losing Stocks

FedEx
FDX • Vol: 2,399,340
Cboe Global Markets
CBOE • Vol: 2,828,165
Qualcomm
QCOM • Vol: 21,186,645
Coterra Energy
CTRA • Vol: 73,319,495
Constellation Energy
CEG • Vol: 11,480,635